Arteries." 1 In that article, we demonstrated deposition of C-reactive protein (CRP) in early human atherosclerotic lesions and its colocalization with the terminal complement complex C5b-9. On the basis of that finding, we suggested that CRP in early atherosclerotic lesions may promote inflammation in the arterial wall by activating the complement system.
The authors of this valuable letter pointed to the fact that CRP in the arterial wall, owing to acidic conditions in inflamed tissue, may be modified into a denatured and reduced form (mCRP) displaying other biological and physiochemical properties than the native form. In the light of increasing evidence for a pivotal role of CRP in atherosclerosis, we agree with the authors' notion that mCRP and its functional properties are most important to study. However, we do not agree with their statement that the antibody that we used for CRP staining (clone CRP-8 from Sigma Chemical Co) ". . . exclusively recognizes a modified form of CRP (mCRP) and not the native CRP molecule." At this point, we would like to cite the specification sheet of the antibody provided by Sigma, which states "monoclonal anti-human C-reactive protein (CRP) recognizes an epitope located on the 24-kDa subunit of denatured reduced CRP applying the immunoblotting technique. It does not cross-react with human serum amyloid P component (SAP), human haptoglobin, human ␣-1 acid glycoprotein, and human IgG, nor with CRP from Limulus. The product displays its reactivity against CRP (native and denatured-reduced) applying ELISA, dot-blot, and immunoblotting technique)" (italics added by us for emphasis). In addition, we have addressed the point raised by Vaith and Potemka in a conversation with the manufacturer, who confirmed the information given in the specification sheet.
On the basis of this information, we suggest that the antibody used in our study is able to detect both the native and the modified form of CRP. In this context, we would like to emphasize that we were not able to demonstrate CRP staining in coronary arteries without any signs of atherosclerotic lesion development. The question remains which form of CRP is the dominating one in early atherosclerotic lesions. Although we did not address this question in our study, extensive costaining with C5b-9 suggests the presence of considerable amounts of native CRP. Furthermore, very recently we demonstrated that native CRP binds to degraded LDL, enhancing complement activation. 2 Immunohistochemical studies complemented these findings in showing that CRP colocalizes with enzymatically modified-LDL in early human atherosclerotic lesions. 2 However, it is most likely that CRP becomes modified in the lesion, at least in intermediate and advanced lesions with increasing acidic conditions, and the significance of this modified CRP needs to be investigated further.
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